Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center.

Autor: null, null, Maschio, Marta, Buttinelli, Carla, Pauletto, Giada, Striano, Salvatore, Salmaggi, Andrea, Terenzi, Riccardo, Daniele, Ornella, Crichiutti, Giovanni, Paladin, Francesco, Rossi, Rosario, Prato, Giulia, Beghi, Ettore, Vigevano, Federico, De Simone, Roberto, Ricci, Federica, Saladini, Marina, Monti, Fabrizio, Casellato, Susanna, Zanoni, Tiziano
Předmět:
Zdroj: PLoS ONE; 7/17/2017, Vol. 12 Issue 7, p1-14, 14p
Abstrakt: Epilepsy is the most common comorbidity in patients with brain tumors. Study Aims: To define characteristics of brain tumor-related epilepsy (BTRE) patients and identify patterns of care. Nationwide, multicenter retrospective cohort study. Medical records of BTRE patients seen from 1/1/2010 to 12/31/2011, followed for at least one month were examined. Information included age, sex, tumor type/treatments, epilepsy characteristics, antiepileptic drugs (AEDs). Time to modify first AED due to inefficacy and/or toxicity was assessed with the Kaplan-Meier method and Cox proportional hazard models were used to identify predictors of treatment outcome. Enrolled were 808 patients (447 men, 361 women) from 26 epilepsy centers. Follow-up ranged 1 to 423 months (median 18 months). 732 patients underwent surgery, 483 chemotherapy (CT), 508 radiotherapy. All patients were treated with AEDs. Levetiracetam was the most common drug. 377 patients (46.7%) were still on first drug at end of follow-up, 338 (41.8%) needed treatment modifications (uncontrolled seizures, 229; side effects, 101; poor compliance, 22). Treatment discontinuation for lack of efficacy was associated with younger age, chemotherapy, and center with <20 cases. Treatment discontinuation for side effects was associated with female sex, enzyme-inducing drugs and center with > 20 cases. About one-half of patients with BTRE were on first AED at end of follow-up. Levetiracetam was the most common drug. A non enzyme-inducing AED was followed by a lower risk of drug discontinuation for SE. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index